Dasatinib in high-risk core binding factor acute myeloid leukemia in first complete remission: A french acute myeloid leukemia intergroup trial

Haematologica

Volumn 100, Issue 6, 2015, Pages 780-785

  Boissel, Nicolas ^a,b   Renneville, Aline ^c,d   Leguay, Thibaut ^e   Lefebvre, Pascale Cornillet ^f   Recher, Christian ^g   Lecerf, Thibaud ^h   Delabesse, Eric ^g   Berthon, Céline ^c   Blanchet, Odile ^h   Prebet, Thomas ⁱ   Pautas, Cecile ^j   Chevallier, Patrice ^k   Leprêtre, Stéphane ^l   Girault, Stéphane ^m   Bonmati, Caroline ⁿ   Guièze, Romain ^o   Himberlin, Chantal ^p   Randriamalala, Edouard ^q   Preudhomme, Claude ^c,d   Jourdan, Eric ^r   Dombret, Hervé ^a,b   Ifrah, Norbert ^h   more..

^a SAINT LOUIS HOSPITAL   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c LILLE UNIVERSITY HOSPITAL   (France)

^d JEAN PIERRE AUBERT RESEARCH CENTER   (France)

^e HAUT LÉVÊQUE HOSPITAL   (France)

^f REIMS UNIVERSITY HOSPITAL   (France)

^g CHU PURPAN   (France)

^h ANGERS UNIVERSITY HOSPITAL   (France)

ⁱ INSTITUT PAOLI CALMETTES   (France)

^j HENRI MONDOR HOSPITAL   (France)

^k NANTES UNIVERSITY HOSPITAL   (France)

^l Service d Hématologie Centre de Lutte Contre le Cancer   (France)

^m DUPUYTREN UNIVERSITY HOSPITAL   (France)

ⁿ CHU NANCY BRABOIS   (France)

^o UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

^p HÔPITAL ROBERT DEBRÉ   (France)

^q POITIERS UNIVERSITY HOSPITAL   (France)

^r NÎMES UNIVERSITY HOSPITAL   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DASATINIB; PROTEIN TYROSINE KINASE; RECEPTOR TYROSINE KINASE KIT; TRANSCRIPTION FACTOR RUNX1; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CORE BINDING FACTOR;

ACUTE MYELOBLASTIC LEUKEMIA; ADULT; ANEMIA; ARTICLE; CLINICAL ARTICLE; CYTOGENETICS; DISEASE FREE SURVIVAL; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DYSPNEA; EDEMA; FATIGUE; FEMALE; GENE MUTATION; HEADACHE; HUMAN; HYPERTENSION; MALE; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; PROTEIN EXPRESSION; RASH; SMALL CELL LUNG CANCER; CLINICAL TRIAL; COHORT ANALYSIS; FOLLOW UP; FRANCE; LEUKEMIA, MYELOID, ACUTE; MIDDLE AGED; PROCEDURES; REMISSION; RISK FACTOR; YOUNG ADULT;

ADULT; ANTINEOPLASTIC AGENTS; COHORT STUDIES; CORE BINDING FACTORS; DASATINIB; FEMALE; FOLLOW-UP STUDIES; FRANCE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; REMISSION INDUCTION; RISK FACTORS; YOUNG ADULT;

EID: 84930519348     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2014.114884     Document Type: Article

References (19)

1. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114(5):937-951
2. Wang Q, Stacy T, Miller JD, et al. The CBFbeta subunit is essential for CBFalpha2 (AML1) function in vivo. Cell. 1996; 87(4):697-708
3. Dombret H, Preudhomme C, Boissel N. Core binding factor acute myeloid leukemia (CBF-AML): is high-dose Ara-C (HDAC) consolidation as effective as you think? Curr Opin Hematol. 2009; 16(2):92-97
4. Yin JAL, O’Brien MA, Hills RK, et al. Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial. Blood. 2012; 120(14):2826-2835
5. Boissel N, Leroy H, Brethon B, et al. Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBFAML). Leukemia. 2006;20(6):965-970
6. Paschka P, Marcucci G, Ruppert AS, et al. Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study. J Clin Oncol. 2006;24(24):3904-3911
7. Paschka P, Du J, Schlenk RF, et al. Secondary genetic lesions in acute myeloid leukemia with inv(16) or t(16;16): a study of the German-Austrian AML Study Group (AMLSG). Blood. 2013;121(1):170-177
8. Jourdan E, Boissel N, Chevret S, et al. Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia. Blood. 2013;121(12):2213-2223
9. Schwartz S, Heinecke A, Zimmermann M, et al. Expression of the C-kit receptor (CD117) is a feature of almost all subtypes of de novo acute myeloblastic leukemia (AML), including cytogenetically good-risk AML, and lacks prognostic significance. Leuk Lymphoma. 1999;34(1-2):85-94
10. Gabert J, Beillard E, van der Velden VHJ, et al. Standardization and quality control studies of “real-time” quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia-a Europe Against Cancer program. Leukemia. 2003; 17(12):2318-2357
11. Mantel N, Byar DP. Evaluation of Response-Time Data Involving Transient States: An Illustration Using Heart-Transplant Data. J Am Stat Assoc. 1974; 69(345):81-86
12. Cox D. Regression models and life-tables. J R Stat Soc Series B Stat Methodol 1972;34:187-202
13. Schittenhelm MM, Shiraga S, Schroeder A, et al. Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. Cancer Res. 2006;66(1):473-481
14. O’Hare T, Walters DK, Stoffregen EP, et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res. 2005; 65(11):4500-4505
15. Shah NP, Kantarjian HM, Kim D-W, et al. Intermittent Target Inhibition With Dasatinib 100 mg Once Daily Preserves Efficacy and Improves Tolerability in Imatinib-Resistant and-Intolerant Chronic-Phase Chronic Myeloid Leukemia. J Clin Oncol. 2008;26(19):3204-3212
16. Gale RE, Green C, Allen C, et al. The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia. Blood. 2008;111(5):2776-2784
17. Kottaridis PD, Gale RE, Langabeer SE, et al. Studies of FLT3 mutations in paired presentation and relapse samples from patients with acute myeloid leukemia: implications for the role of FLT3 mutations in leukemogenesis, minimal residual disease detection, and possible therapy with FLT3 inhibitors. Blood. 2002;100(7):2393-2398
18. Allen C, Hills RK, Lamb K, et al. The importance of relative mutant level for evaluating impact on outcome of KIT, FLT3 and CBL mutations in core-binding factor acute myeloid leukemia. Leukemia. 2013; 27(9):1891-1901
19. Cairoli R, Beghini A, Morello E, et al. Imatinib mesylate in the treatment of Core Binding Factor leukemias with KIT mutations. A report of three cases. Leuk Res. 2005;29(4):397-400.